MA33705B1 - Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale - Google Patents

Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale

Info

Publication number
MA33705B1
MA33705B1 MA32860A MA32860A MA33705B1 MA 33705 B1 MA33705 B1 MA 33705B1 MA 32860 A MA32860 A MA 32860A MA 32860 A MA32860 A MA 32860A MA 33705 B1 MA33705 B1 MA 33705B1
Authority
MA
Morocco
Prior art keywords
corticosteroid
inhibitor
pde
inhale
montelukast acid
Prior art date
Application number
MA32860A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA33705B1 publication Critical patent/MA33705B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA32860A 2007-10-25 2010-05-20 Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale MA33705B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25
PCT/CA2008/001874 WO2009052624A1 (en) 2007-10-25 2008-10-23 Combination therapy

Publications (1)

Publication Number Publication Date
MA33705B1 true MA33705B1 (fr) 2012-11-01

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32860A MA33705B1 (fr) 2007-10-25 2010-05-20 Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale

Country Status (19)

Country Link
US (1) US20100210611A1 (enExample)
EP (1) EP2211863A4 (enExample)
JP (1) JP2011500731A (enExample)
KR (1) KR20100072295A (enExample)
CN (1) CN101909626A (enExample)
AU (1) AU2008316283A1 (enExample)
CA (1) CA2701956A1 (enExample)
CO (1) CO6270213A2 (enExample)
CR (1) CR11439A (enExample)
DO (1) DOP2010000122A (enExample)
GT (1) GT201000107A (enExample)
IL (1) IL205182A0 (enExample)
MA (1) MA33705B1 (enExample)
MX (1) MX2010004529A (enExample)
NI (1) NI201000069A (enExample)
NZ (1) NZ584876A (enExample)
RU (1) RU2470639C2 (enExample)
WO (1) WO2009052624A1 (enExample)
ZA (1) ZA201002562B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
EA007736B1 (ru) * 2001-09-19 2006-12-29 Алтана Фарма Аг Комбинация ингибитора pde и антагониста лейкотриенового рецептора
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
US7553853B2 (en) * 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1931338A4 (en) * 2005-09-28 2009-05-27 Merck Frosst Canada Inc AEROSOL POWDER FORMULATION COMPRISING A TAMISED LACTOSE

Also Published As

Publication number Publication date
CN101909626A (zh) 2010-12-08
MX2010004529A (es) 2010-05-10
RU2010120806A (ru) 2011-11-27
JP2011500731A (ja) 2011-01-06
EP2211863A1 (en) 2010-08-04
WO2009052624A1 (en) 2009-04-30
WO2009052624A9 (en) 2010-11-25
CA2701956A1 (en) 2009-04-30
NI201000069A (es) 2010-08-23
ZA201002562B (en) 2011-06-29
CO6270213A2 (es) 2011-04-20
IL205182A0 (en) 2010-11-30
KR20100072295A (ko) 2010-06-30
CR11439A (es) 2010-06-21
GT201000107A (es) 2012-03-13
DOP2010000122A (es) 2010-07-15
AU2008316283A1 (en) 2009-04-30
NZ584876A (en) 2012-06-29
US20100210611A1 (en) 2010-08-19
EP2211863A4 (en) 2012-07-25
RU2470639C2 (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA33705B1 (fr) Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
AU2008317965C1 (en) Osmolyte-containing preparation for use in case of dry mucous membranes
Davenport et al. Systemic and behavioral effects of intranasal administration of silver nanoparticles
MA33299B1 (fr) Nouvelle formulation de naproxène
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
DE60231826D1 (de) Abgabevorrichtung für arzneimittel
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
CA2474479A1 (en) Composition for inhalation
JP6234899B2 (ja) 喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
MA29227B1 (fr) 4-phenyltetrahydroisoquinoline substituees, leur procedes de fabrication, leur utilisation en tant que medicament et medicament les contenant
Ding et al. Characterization of dental dust particles and their pathogenicity to respiratory system: a narrative review
JP2008533072A5 (enExample)
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
NO20054180L (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
JP2011500731A5 (enExample)
BR0313199A (pt) Derivados h de ácido endiândrico como inibidores de c-maf para o emprego contra asma
JP2006316063A (ja) ペトロラタムを基にした鼻用軟膏
MA30567B1 (fr) Dérivés d'acide phénylacétique.
IL168308A (en) Compositions containing roflumilast and formoterol
NO20090812L (no) Fenyl-prenyl-eter derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
MA52375A1 (fr) Inhibiteurs de cdk8/19